Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- What is leishmaniasis?
- Leishmaniases: a Neglected Tropical Disease (NTD)
- Leishmaniasis
- Global burden & geographical distribution of VL
- Global VL incidence trends: 2005–2020
- Parasite, vector, host reservoir
- VL in East Africa and South Asia
- VL clinical presentation
- L. donovani infection
- VL treatment in immunocompetent patients
- VL treatment in HIV co-infected patients
- VL disease control strategies
- Strategy 1: early diagnosis and treatment
- VL endemic areas in South Asia
- VL endemic areas in East Africa
- Diagnosis: clinical case definition of suspect VL
- Diagnosis: parasitology
- Amastigotes under the microscope
- Serology: DAT (Direct Agglutination Test)
- DAT is still possible in simple field labs
- Serological lateral flow RDT: simple, fast, low cost
- Diagnostic algorithm for VL in South Asia
- Diagnostic algorithm for VL in East Africa
- Patient treatment and mortality in Northwest Ethiopia
- Aim of drug treatment of VL
- Anti-leishmanial drugs
- Pentavalent antimonials (SbV)
- Amphotericin B deoxicholate
- Liposomal amphotericin B (L-AmB)
- Miltefosine (MF)
- Paromomycin (PM)
- Drug combinations
- Treatment
- Treatment with liposomal amphotericin B
- Treatment in East Africa
- VL + HIV co-infection
- Strategy 2: control of reservoir hosts
- Strategy 3: vector control
- Potentials for vector control
- Insecticide-Treated Nets (ITNs)
- ITNs in Sudan
- Bed net utilisation
- Strategy 4: epidemic response
- Strategy 5: vaccination
- Conclusions
- Thank you
Topics Covered
- Visceral Leishmaniasis (VL)
- Vector-borne disease
- Neglected Tropical Diseases (NTDs)
- Global epidemiology of VL
- Clinical presentation of VL
- VL disease control
- VL/HIV co-infection
- Early diagnosis and treatment
- Anti-leishmanial drugs
- Control of reservoir hosts and vectors
- Epidemic response
- Vaccination
- L. donovani infection
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Ritmeijer, K. (2023, November 30). Visceral leishmaniasis control [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/DQKR6244.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Koert Ritmeijer.
I am the Neglected
Tropical Disease Advisor
at Médecins Sans Frontières
based in Amsterdam.
I have more than 25
years of experience
in dealing with leishmaniasis.
That is what the talk
today will be about,
visceral leishmaniasis and
the control of the disease.
0:20
Leishmaniasis is a
disease that is caused
by vector-borne
protozoan parasites,
and is transmitted by
infected female sandflies.
It is endemic in 98 countries,
with an estimated population
at risk of 350 million,
but it is very much
underreported.
0:39
This is because leishmaniasis
is a neglected tropical disease.
The World Health
Organization has a list
of 20 neglected
tropical diseases
and some of them are fairly
easy to treat or to control,
for instance with Mass
Drug Administration
but leishmaniasis is among
the more neglected tropical
diseases because it is
an intensified disease
management NTD.
This means that the disease
is difficult to diagnose,
difficult to treat, and
difficult to control.
It affects the poorest and
most neglected populations.
Neglect means that the disease
is neglected by
local governments
because it is not prioritized
as an important public
health problem,
therefore there's very
little investment
in control programs.
It is neglected by
institutional donors
because they usually focus
on the low hanging fruits
where they can easily
book successes
in achieving control.
That means that there's
very little funding
for control programs for
diseases like leishmaniasis.
Thirdly and also
of importance is
the neglect by
pharmaceutical industries.
Because the disease affects
the poorest populations
it is not a profitable market
and therefore there is
very little investment
in research and development
for better diagnostics,
drugs and vaccines.